predicted Monday that it would earn "in the range of 55 cents" per share for 2005, a penny below the consensus Wall Street estimate.
The Summit, N.J.-based company also said it expected sales to reach a range of $525 million in 2005. The consensus of analysts polled by Thomson First Call is $502 million.
The company predicted it would earn 9 cents a share for the three months ended Dec. 31. That matches the fourth-quarter 2004 consensus from Thomson First Call. The company's EPS estimate excludes a $6 million payment to another drug company and a $2 million charge associated with relocating its corporate headquarters.
The company will publish full-year 2004 results on Jan. 27.
The announcement sent the company's shares up $1.33, or 4.9%, to $28.56.